country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-146710

Copy Link Print Information

RET-IN-16

RET-IN-16 is a potent and selective RET inhibitor with IC₅₀s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for RET(WT), RET(M918T), RET(V804L), RET(V804M), RET-CCDC6 and RET-KIF5B, respectively. RET-IN-16 has anticancer effects.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 2259657-48-0
Formule: C₃₁H₂₉F₃N₈O₂
Masse moléculaire:602.61

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (280 KB)

RET-IN-16 Chemical Structure

CAS No.: 2259657-48-0

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

IC₅₀: 3.98 nM (RET(WT)), 8.42 nM (RET(M918T)), 15.05 nM (RET(V804L)), 7.86 nM (RET(V804M)), 5.43 nM (RET-CCDC6), 8.86 nM (RET-KIF5B)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	GI₅₀	2.947 μM Compound: 9x	Antiproliferative activity against human A-375 cells measured after 48 hrs by MTS assay Antiproliferative activity against human A-375 cells measured after 48 hrs by MTS assay	[PMID: 32882611]
A549	GI₅₀	3.393 μM Compound: 9x	Antiproliferative activity against human A549 cells measured after 48 hrs by MTS assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTS assay	[PMID: 32882611]
BaF3	GI₅₀	8.03 μM Compound: 9x	Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay	[PMID: 32882611]
MDA-MB-231	GI₅₀	2.428 μM Compound: 9x	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTS assay	[PMID: 32882611]
NCI-H3122	GI₅₀	5.679 μM Compound: 9x	Antiproliferative activity against human NCI-H3122 cells measured after 48 hrs by MTS assay Antiproliferative activity against human NCI-H3122 cells measured after 48 hrs by MTS assay	[PMID: 32882611]

In Vitro

RET-IN-16 (compound 9x) (0.005-10 μM; 48 hours) exhibits potent activity against CCDC6-RET-Ba/F3 and KIF5B-RET-Ba/F3 with GI₅₀ of 9 nM and 17 nM, respectively^[1].
RET-IN-16 (1 μM; 48 hours) selectively suppresses the proliferation of CCDC6-RET fusion cells^[1].
RET-IN-16 (50 and 100 μM; 4 hours) remarkably blocks the autophosphorylation of RET in KIF5B-RET and KIF5B-RET^V804M Ba/F3 cells, and the phosphorylation of the adapter protein SHC is also inhibited with a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:

LC-2/ad, A549, H3122, MDA-MB-231 and A375, SKGT4, HepG2, KYSE450 and BGC823 cells^[1]
Concentration:

1 μM
Incubation Time:

48 hours
Result:

Potently suppressed the proliferation of LC-2/ad NSCLC cells harboring the CCDC6-RET fusion, but dramatically decreased potency against other RET-negative cancer cells.

Western Blot Analysis

Cell Line:

KIF5B-RET and KIF5B-RET^V804M Ba/F3 cells^[1]
Concentration:

50 and 100 μM
Incubation Time:

4 hours
Result:

Remarkably blocked the autophosphorylation of RET, and the phosphorylation of the adapter protein SHC was also inhibited in a dose-dependent manner.

In Vivo

RET-IN-16 (1 mg/kg; IV; single) exhibits a good drug exposure (AUC_0-t = 6959 ± 762 ng·h/mL) and a moderate half-life (T_1/2 = 4.28 ± 0.43 h)^[1].
RET-IN-16 (10 mg/kg; PO; single) exhibits a low maximum plasma concentration (C_max = 194 ± 47 ng·h/mL) and drug exposure (AUC_0-t = 2112 ± 117 ng·h/mL)^[1].
RET-IN-16 (30 and 50 mg/kg; IV; daily; for 8 days) suppresses tumor growth in a dose-dependent manner, and significantly suppresses p-RET and p-SHC in both KIF5B-RET and KIF5B-RET^V804M in tumor tissues, as well as significantly induces apoptosis in vivo^[1].
Pharmacokinetic Parameters of RET-IN-16 in male Sprague-Dawley rats^[1].

	IV (1 mg/kg)	PO (10 mg/kg)
T_1/2 (h)	4.28 ± 0.43	7.59 ± 1.02
T_max (h)	0.083 ± 0	0.75 ± 0.43
C_max (ng/mL)	6097 ± 623	194 ± 47
AUC_0-t (ng/mL·h)	6959 ± 762	2112 ± 117
AUC_0-∞ (ng/mL·h)	7014 ± 753	2343 ± 157
F (%)		3.0

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats^[1]
Dosage:

1 mg/kg for IV, 10 mg/kg for PO
Administration:

IV and PO; single (Pharmacokinetic Analysis)
Result:

Exhibited a good drug exposure (AUC_0-t = 6959 ± 762 ng·h/mL) and a moderate half-life (T_1/2 = 4.28 ± 0.43 h) at 1 mg/kg IV; observed a low maximum plasma concentration (C_max = 194 ± 47 ng·h/mL) and drug exposure (AUC_0-t = 2112 ± 117 ng·h/mL) at 10 mg/kg PO.

Animal Model:

Half male and female BALB/c-nu mice (6-8 weeks; injected with KIF5B-RET Ba/F3 and KIF5B-RETV804M Ba/F3)^[1]
Dosage:

30 and 50 mg/kg
Administration:

IV; daily; for 8 days
Result:

Suppressed tumor growth in a dose-dependent manner, and significantly suppressed p-RET and p-SHC in both KIF5B-RET and KIF5B-RET^V804M in tumor tissues, as well as significantly induced apoptosis in vivo.

Chemical Information

CAS No. 2259657-48-0
Masse moléculaire 602.61
Formule C₃₁H₂₉F₃N₈O₂
SMILES

CC1=CC=C(C=C1OC2=C3C=NNC3=NC(C4=CN=CC=C4)=N2)C(NC5=CC(C(F)(F)F)=C(C=C5)CN6CCN(CC6)C)=O
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Li X, Su J, Yang Y, et al. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. Eur J Med Chem. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis